Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    9500606 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
Conditions: Melanoma;   Neoplasm Metastasis
Interventions: Drug: GP100 peptide;   Drug: IL-2
2 Unknown  Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Biological: URLC10, TTK and KOC1
3 Unknown  Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
Condition: Esophageal Cancer
Intervention: Biological: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
4 Completed Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
Conditions: Melanoma;   Neoplasm Metastasis
Intervention: Biological: Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
5 Recruiting Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
6 Suspended Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Condition: Bile Duct Cancer
Interventions: Biological: Peptide vaccine for URLC10;   Drug: Gemcitabine
7 Completed A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Condition: Melanoma
Intervention: Biological: gp100 human melanoma peptide

Indicates status has not been verified in more than two years